Corline Biomedical AB (OSTO:CLBIO) Cyclically Adjusted Revenue per Share: kr0.43 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:CLBIO Corline Biomedical AB OSTO:CLBIO
43 GF Score
Price kr18.00
GF Value kr4.80
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Corline Biomedical AB Cyclically Adjusted Revenue per Share?

Corline Biomedical AB OSTO:CLBIO +1.41% 43 Cyclically Adjusted Revenue per Share is kr0.43 as of Mar. 2026. GuruFocus rates OSTO:CLBIO with a GF Score™ of 43/100 and a GF Value™ of kr4.80 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Corline Biomedical AB's adjusted revenue per share for the three months ended in Mar. 2026 was kr0.167. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr0.43 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Corline Biomedical AB's average Cyclically Adjusted Revenue Growth Rate was 4.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-21), Corline Biomedical AB's current stock price is kr18.00. Corline Biomedical AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr0.43. Corline Biomedical AB's Cyclically Adjusted PS Ratio of today is 41.86.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Corline Biomedical AB was 50.98. The lowest was 15.80. And the median was 31.75.


Corline Biomedical AB  (OSTO:CLBIO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Corline Biomedical AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=18.00/0.43
=41.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Corline Biomedical AB was 50.98. The lowest was 15.80. And the median was 31.75.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Corline Biomedical AB Cyclically Adjusted Revenue per Share Related Terms


Corline Biomedical AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Corline Biomedical AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corline Biomedical AB Cyclically Adjusted Revenue per Share Chart

Corline Biomedical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.38 0.40 0.42

Corline Biomedical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.41 0.41 0.42 0.43

OSTO:CLBIO vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Corline Biomedical AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corline Biomedical AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corline Biomedical AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Corline Biomedical AB's Cyclically Adjusted PS Ratio falls into.


OSTO:CLBIO
43GF Score
Corline Biomedical AB OSTO:CLBIO
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corline Biomedical AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Corline Biomedical AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.167/133.5600*133.5600
=0.167

Current CPI (Mar. 2026) = 133.5600.

Corline Biomedical AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.030 101.019 0.040
201609 0.012 101.138 0.016
201612 0.016 102.022 0.021
201703 0.017 102.022 0.022
201706 0.008 102.752 0.010
201709 0.009 103.279 0.012
201712 0.013 103.793 0.017
201803 0.021 103.962 0.027
201806 0.023 104.875 0.029
201809 0.022 105.679 0.028
201812 0.034 105.912 0.043
201903 0.009 105.886 0.011
201906 0.022 106.742 0.028
201909 0.008 107.214 0.010
201912 0.024 107.766 0.030
202003 0.011 106.563 0.014
202006 0.036 107.498 0.045
202009 0.022 107.635 0.027
202012 0.152 108.296 0.187
202103 0.087 108.360 0.107
202106 0.063 108.928 0.077
202109 0.045 110.338 0.054
202112 0.151 112.486 0.179
202203 0.143 114.825 0.166
202206 0.242 118.384 0.273
202209 0.327 122.296 0.357
202212 0.352 126.365 0.372
202303 0.344 127.042 0.362
202306 0.283 129.407 0.292
202309 0.247 130.224 0.253
202312 0.291 131.912 0.295
202403 0.174 132.205 0.176
202406 0.105 132.716 0.106
202409 0.082 132.304 0.083
202412 0.088 132.987 0.088
202503 0.084 132.825 0.084
202506 0.089 133.699 0.089
202509 0.053 133.480 0.053
202512 0.083 133.390 0.083
202603 0.167 133.560 0.167

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr0.43 mean?
Corline Biomedical AB (OSTO:CLBIO) has a Cyclically Adjusted Revenue per Share of kr0.43 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Corline Biomedical AB and its competitors.
Is Corline Biomedical AB's Cyclically Adjusted Revenue per Share too high?
Corline Biomedical AB's current Cyclically Adjusted Revenue per Share is kr0.43. Overall, Corline Biomedical AB has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corline Biomedical AB's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Corline Biomedical AB's Cyclically Adjusted Revenue per Share of kr0.43 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Corline Biomedical AB and its competitors. Corline Biomedical AB's current Cyclically Adjusted Revenue per Share is kr0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corline Biomedical AB stock overvalued right now?
Based on GuruFocus' analysis, Corline Biomedical AB (OSTO:CLBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr4.80, compared to a current price of kr18.00 — trading 275% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr0.43. Corline Biomedical AB's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Corline Biomedical AB (OSTO:CLBIO), the current Cyclically Adjusted Revenue per Share is kr0.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corline Biomedical AB (OSTO:CLBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Corline Biomedical AB stock appears to be overvalued. The current stock price of kr18.00 is trading 275% above its estimated GF Value™ of kr4.80. GuruFocus considers Corline Biomedical AB to be Significantly Overvalued.

Key valuation signals for OSTO:CLBIO:

  • Cyclically Adjusted Revenue per Share: kr0.43
  • GF Value™: kr4.80 vs. price of kr18.00 (275% above fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the OSTO:CLBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Corline Biomedical AB Business Description

Address Lefflersgatan 5, Uppsala, SWE, 754 50
Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.
43GF Score

Get the complete analysis for OSTO:CLBIO

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr18.00
Price
kr4.80
GF Value